高血压肾损害患者IL-6-572、IL-6-174基因多态性及其与贝那普利治疗反应的相关性

目的探讨白细胞介素-6(interleukin 6,IL-6)-572、IL-6-174基因多态性与高血压肾损害及贝那普利治疗反应的相关性。方法入选284例初次诊断高血压病的患者,根据24h尿蛋白排泄率(urinary albumin excretion,UAER)水平分为高血压组(UAER<20μg/min)和高血压肾损害组(UAER≥20μg/min)。检测IL-6水平及IL-6-572、IL-6-174基因多态性。然后用贝那普利干预,观察具备IL-6-572、IL-6-174的不同基因型的患者的治疗反应。结果高血压肾损害组中,IL-6-572的CG基因型、IL-6-174的GG基因型比例最高。贝那普利治疗对具有IL-6-572GG基因型、IL-6-174CC基因型的高血压肾损害患者治疗效果最佳。结论IL-6-572、IL-6-174基因多态性与高血压肾损害及其对贝那普利治疗的反应相关。

Association of Interleukin-6-174G/C Polymorphism with the Risk of Diabetic Nephropathy in Type 2 Diabetes:A Meta-analysis

Previous studies reported the association between interleukin-6(IL-6)-174G/C gene polymorphism and the risk of diabetic nephropathy in type 2 diabetes mellitus(T2DN).However,the results remain controversial.In the present study,we conducted a meta-analysis to further examine this relationship between IL-6-174G/C gene polymorphism and T2DN.Three databases(PubMed,SinoMed and ISI Web of Science)were used to search clinical case-control studies about IL-6-174G/C polymorphism and T2DN published until Apr.14,2018.Fixed-or random-effects n lodels were used to calculate the effect sizes of odds ratio(OR)and 95%confide nee intervals(95%CI).Moreover,subgroup analysis was performed in tenns of the excretion rate of albuminuria.All the statistical analyses were con ducted using Stata 12.0.A total of 11 case-control studies were included in this study,involving 1203 cases of T2DN and 1571 cases of T2DM without DN.Metaanalysis showed that there was an association between IL-6-174G/C polymorphism and increased risk of T2DN under the allelic and recessive genetic models(G vs.C:OR=1.10,95%CI 1.03-1」&P=0.006;GG vs.CC+GC:OR=1.11,95%CI 1.02-1.21,P=0.016).In the subgroup analysis by albuminuria,a significant association of IL-6-174G/C polymorphism with risk of T2DN was noted in the microalbuminuria group under the recessive model(OR=1.54,95%CI 1.02-2.32,P=0.038).In conclusion,this meta-analysis suggests that IL-6-174G/C gene polymorphism is associated with the risk of T2DN.

炎症因子与乳腺癌患者辅助放射治疗期间癌性疲劳的相关性

目的探讨炎症因子与乳腺癌患者辅助放射治疗期间癌性疲劳的相关性。方法选取术后辅助放射治疗的乳腺癌患者,按埃德蒙顿症状评估系统的疲劳评分将其分为疲劳组及观察组,比较2组血清炎症因子CRP、IL-6及可溶性肿瘤坏死因子受体2(sTNFR2)的差异;检测每位患者的疲劳相关炎症因子编码基因启动子的单核苷酸多态性,分析炎症因子相关基因分型与放射治疗结束时疲劳评分的相关性。结果共61例患者入组,其中疲劳组37例。观察组24例,癌性疲劳的发生率为60.6%。疲劳组伴有恶心、焦虑及厌食者较观察组多(P均<0.05)。疲劳组放射治疗后血清IL-6水平较治疗前高(P<0.001),观察组放射治疗前、后IL-6水平比较差异无统计学意义(P>0.05)。IL-6水平与疲劳的发生呈正相关(r_(s)=0.51,P<0.001)。2组治疗前后CRP及sTNFR2水平比较差异均无统计学意义(P均>0.05)。IL-6启动子编码基因IL6-174 GG基因分型的乳腺癌患者放射治疗结束时的疲劳评分高于CC基因分型患者(P=0.001)。结论血清IL-6水平及IL6-174 GG基因分型或与乳腺癌辅助放射治疗期间癌性疲劳的产生有关。